Synthesis and in vitro human skin penetration of oligo- and polymeric ethylene glycol carbonates of zidovudine and stavudine

David D. N'Da; Jaco C. Breytenbach; J Wilma Breytenbach

doi:10.1055/s-0031-1296328

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2010; 60(9): 575-582
DOI: 10.1055/s-0031-1296328

Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics

Editio Cantor Verlag Aulendorf (Germany)

Synthesis and in vitro human skin penetration of oligo- and polymeric ethylene glycol carbonates of zidovudine and stavudine

David D. N'Da

¹Department of Pharmaceutical Chemistry, School of Pharmacy, North-West University, Potchefstroom, South Africa

,

Jaco C. Breytenbach

¹Department of Pharmaceutical Chemistry, School of Pharmacy, North-West University, Potchefstroom, South Africa

,

J Wilma Breytenbach

²Statistical Consultation Services, North-West University, Potchefstroom, South Africa

› Author Affiliations

Abstract

In continuation of studies focusing on the transdermal delivery of antiretroviral (ARV) drugs, the skin permeation ability of synthesized homologous series of both oligomeric and polymeric ethylene glycol (PEG) carbonates of zidovudine (3'-azido-3'-deoxythymidine, AZT, CAS 30516-87-1) and stavudine (2',3'-dideoxy-2',3'-didehydrothymine, d4T, CAS 3056-17-5) was evaluated in vitro through excised human skin in phosphate buffered solution (PBS) (0.01 M, pH 7.4) at 37°C by using Franz cell diffusion methodology. The results revealed that all the derivatives permeated the skin regardless of the series. However, the derivative having three ethylene glycol repeating units was the most effective permeant in each series. The skin permeation rates of zidovudine and stavudine were enhanced by factors in the 2-4, and 1-3 range through these carbonates, respectively.

Key word

Antiretroviral drugs - Ethylene glycol - Ethylene oxide - Poly(ethylene glycol) - Stavudine - Transdermal penetration - Zidovudine

Full Text

References

References
1 Bonina FP, Puglia C, Barbuzzi T, deCaprariis P, Palagiano F, Rimoli MG et al. In vitro and in vivo evaluation of poly-oxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci. 2001; 14: 123-34
2 Sloan KB.. Prodrugs for dermal delivery. Adv Drug Del Rev. 1989; 3: 67-101
3 Sloan KB In: Prodrugs: topical and ocular drug delivery. Sloan KB. editor. New York: Marcel Dekker; 1992: 17-116
4 Naik A, Kalia YN, Guy RH.. Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technol Today. 2000; 3: 318-26
5 Bonina F, Puglia C, Rimoli MG, Avallone L, Abignente E, Boatto G et al. Synthesis and in vitro chemical and enzymatic stability of glycosyl 3'-azido-3'-deoxythymidine derivatives as potential anti-HIV agents. Eur J Pharm Sci. 2002; 16: 167-74
6 Klecker Jr RW, Collins JM, Yarchoan R, Thomas R, Jenkins JF, Broder S et al. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimi-dine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987; 41: 407-12
7 Kim DD, Chien YW.. Transdermal delivery of dideoxynu-cleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J Pharm Sci. 1996; 85: 214-9
8 Panchagnula R, Patel JR.. Transdermal delivery of azidothy-midine (AZT) through rat skin ex-vivo. Pharm Sci. 1997; 3: 83-7
9 Kumar PN, Sweet DE, McDowell JA, Symonds W, Lou Y, Hetherington S et al. Safety and pharmacokinetics of abaca-vir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-in-fected adults. Antimicrob Agents Chemother. 1999; 43: 603-8
10 McEvoy GK.. AHFS Drug Information. 2002; 59: 711-4
11 Simpson MV, Chin CD, Keilbaugh SA, Lin TS, Prusoff WH.. Studies on the inhibition of mitochondrial DNA replication by 3'-azido-3'-deoxythymidine and other dideoxynucleo-side analogs which inhibit HIV-1 replication. Biochem Pharmacol. 1989; 38: 1033-6
12 Kaduka TN.. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000; 22: 685-708
13 Puglia C, Filosa R, Peduto A, deCaprariis P, Rizza L, Bonina F et al. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS Pharm Sci Tech. 2006; 73: E1-E9
14 Kiptoo PK, Paudel KS, Hammell DC, Hamad MO, Crooks PA, Stinchcomb AL.. In vivo evaluation of a transdermal co-drug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci. 2008; 33: 371-9
15 Gerber M, Breytenbach JC, du Plessis J.. Transdermal penetration of zalcitabine, lamivudine and synthesised N-acyl lamivudine esters. Int J Pharm. 2008; 351: 186-93
16 Ballico M, Cogoi S, Drioli S, Bonora GM. Postsynthetic conjugation of biopolymers with high molecular mass poly (ethylene glycol): optimization of a solution process tested on synthetic oligonucleotides. Bioconjug Chem. 2003; 14: 1038-43
17 N'Da DD, Breytenbach JC.. Synthesis of methoxypoly(ethy-lene glycol) carbonate prodrugs of zidovudine and penetration through human skin in vitro. J Pharm Pharmacol. 2009; 61: 721-31
18 Jordan FL. Mixture for transdermal delivery of low and high molecular weight compounds (Patent US 07316820). Official Gazette of the United States Patent and Trademark Office Patents, 2007.
19 Sloan KB, Koch SAM, Siver KG.. Mannich base derivatives of theophylline and 5-fluorouracil: syntheses, properties and topical delivery characteristics. Int J Pharm. 1984; 21: 251-64
20 Rautio J, Nevalainen T, Taipale H, Vepsalainen J, Gynther J, Pedersen T et al. Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl)propion-ic acid as novel naproxen prodrugs for dermal drug delivery. Pharm Res. 1999; 16: 1172-8
21 Li J, Zhai YL, Zhang B, Deng LD, Xu YS, Dong AJ.. Methoxy poly(ethylene glycol)-block-poly(D,L-lactic acid) copolymer nanoparticles as carriers for transdermal drug delivery. Polymer Int. 2008; 57: 268-74
22 Bodansky M.. Synthesis of peptides by aminolysis of nitro-phenyl esters. Nature. 1955; 175: 685-
23 Magnusson BM, Anissimov YG, Cross SE, Roberts MS.. Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol. 2004; 122: 993-9
24 Harrison SM, Barry BW, Dugard PH.. Effects of freeze drying on human skin permeability. J Pharm Pharmacol. 1984; 36: 261-2
25 StatSoft Inc. Statistica (data analysis software system), version 8.0; 2007. Available from: www.statsoft.com
26 Steyn AGW, Smit CF, Du Toit SHC, Strasheim C In: Modern statistics in practice. van Schaik JL. editor. Pretoria: University of South Africa; 1998: 604-606
27 Kendall MG, Stuart A. The advanced theory of statistics. Chapter 10 London: Charles Griffin; 1969
28 Shaik AAG, Sivaram S.. Organic carbonates. Chem Rev. 1996; 96: 951-76
29 N'Da DD, Breytenbach JC, Legoabe LJ, Breytenbach JW.. Synthesis and in vitro transdermal penetration of methoxy-poly(ethylene glycol) carbonate derivatives of stavudine. Med Chem. 2009; 5: 497-506
30 Sloan K, Wasdoo S, Rautio J.. Design for optimized topical delivery: Prodrugs and a paradigm change. Pharm Res. 2006; 23: 2729-47
31 Billich A, Vyplel H, Grassberger M, Schmook F, Steck A, Stuez A.. Novel cyclosporin derivatives featuring enhanced skin penetration despite increased molecular weight. Bioorg Med Chem. 2005; 13: 3157-67
32 Solomons TW, Fryhle CB. Organic Chemistry. New York: John Wiley & Sons; 2007: 1280
33 Kozlowski A, Charles SA, Harris JM.. Development of pegy-lated interferons for the treatment of chronic hepatitis C. Bio Drugs. 2001; 15: 419-29